| GlaxoSmithKline AG - Trelegy Ellipta, Einzeldosiertes Pulver zur Inhalation |
| 66808 | | 01 | | Trelegy Ellipta | | Einzeldosiertes Pulver zur Inhalation | | R03AL08 | | Vilanterol, Umeclidinium Bromide and Fluticasone Furoate | | 20.09.2018 | | |
|
| Composition |
| fluticasoni furoas 92 µg, umeclidinium 55 µg ut umeclidinii bromidum 65.3 µg, vilanterolum 22 µg ut vilanteroli trifenatas, magnesii stearas, lactosum monohydricum, ad pulverem pro dosi, doses pro vase 30. |
| Packungsbestandteile |
| Einzeldosiertes Pulver zur Inhalation | | | | | | | | Principe actif | Concentr. |
|---|
| Fluticasoni Furoas | 92 µg | | Umeclidinium | 55 µg | | Vilanterolum | 22 µg |
| | BAG: Principe actif | Concentr. |
|---|
| Fluticasoni Furoas | 92 mcg | | Umeclidinium | 55 mcg | | Vilanterolum | 22 mcg |
| | | | Agents auxilliaires |
|---|
| Lactose Monohydrate | | Magnesii Stearas |
| |
|
|
